|
US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
ATE303385T1
(de)
*
|
2000-08-04 |
2005-09-15 |
Warner Lambert Co |
Verfahren zur herstellung von 2-(4-pyridyl)amino- 6-dialkylolxaphenyl-pyrido(2,3-d)pyrimidon-7-on derivaten
|
|
US6960662B2
(en)
*
|
2000-08-04 |
2005-11-01 |
Warner-Lambert Company |
Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
|
|
JP4064818B2
(ja)
*
|
2001-02-12 |
2008-03-19 |
エフ．ホフマン−ラ ロシュ アーゲー |
６−置換ピリド−ピリミジン類
|
|
JP4166991B2
(ja)
|
2001-02-26 |
2008-10-15 |
田辺三菱製薬株式会社 |
ピリドピリミジンまたはナフチリジン誘導体
|
|
US20030100572A1
(en)
*
|
2001-06-21 |
2003-05-29 |
Ariad Pharmaceuticals,Inc. |
Novel pyridopyrimidones and uses thereof
|
|
US20050154046A1
(en)
*
|
2004-01-12 |
2005-07-14 |
Longgui Wang |
Methods of treating an inflammatory-related disease
|
|
BRPI0307057B8
(pt)
|
2002-01-22 |
2021-05-25 |
Warner Lambert Co |
compostos 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
|
|
DE60316581T2
(de)
|
2002-08-06 |
2008-07-03 |
F. Hoffmann-La Roche Ag |
6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
|
|
US7112676B2
(en)
|
2002-11-04 |
2006-09-26 |
Hoffmann-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
|
US7759336B2
(en)
|
2002-12-10 |
2010-07-20 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic compounds and medicinal use thereof
|
|
KR20050111636A
(ko)
|
2003-04-10 |
2005-11-25 |
에프. 호프만-라 로슈 아게 |
피리미도 화합물
|
|
JP4053073B2
(ja)
*
|
2003-07-11 |
2008-02-27 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
選択的ｃｄｋ４阻害剤のイセチオン酸塩
|
|
PL2256106T3
(pl)
|
2003-07-22 |
2015-08-31 |
Astex Therapeutics Ltd |
Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
|
|
KR20060036105A
(ko)
*
|
2003-07-29 |
2006-04-27 |
제논 파마슈티칼스 인크. |
피리딜 유도체 및 그의 치료제로서의 용도
|
|
DE602004005238T2
(de)
*
|
2003-11-13 |
2007-11-08 |
F. Hoffmann-La Roche Ag |
Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7-one
|
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
US7968557B2
(en)
*
|
2004-02-14 |
2011-06-28 |
Novartis Ag |
Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors
|
|
BRPI0507852A
(pt)
*
|
2004-02-18 |
2007-07-10 |
Warner Lambert Co |
2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas
|
|
BRPI0509580A
(pt)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
|
SI2298768T1
(en)
*
|
2004-06-11 |
2013-01-31 |
Japan Tobacco Inc |
5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyridoS2,3-dCpyrimidine derivatives and related compounds for the treatment of cancer
|
|
CA2586761A1
(en)
|
2004-11-10 |
2006-05-18 |
Genzyme Corporation |
Methods of treating diabetes mellitus
|
|
US20060142312A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Pfizer Inc |
C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
|
|
AU2006207321B2
(en)
*
|
2005-01-21 |
2012-09-06 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
AU2006207322A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors and further antitumor agents
|
|
ES2552338T3
(es)
*
|
2005-01-21 |
2015-11-27 |
Astex Therapeutics Limited |
Compuestos farmacéuticos
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
WO2006090853A1
(ja)
|
2005-02-25 |
2006-08-31 |
Ono Pharmaceutical Co., Ltd. |
含窒素複素環化合物およびその医薬用途
|
|
TW200724142A
(en)
*
|
2005-03-25 |
2007-07-01 |
Glaxo Group Ltd |
Novel compounds
|
|
MY145281A
(en)
*
|
2005-03-25 |
2012-01-13 |
Glaxo Group Ltd |
Novel compounds
|
|
EP2559690B1
(en)
|
2005-05-10 |
2016-03-30 |
Incyte Holdings Corporation |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
|
KR100734837B1
(ko)
*
|
2005-09-16 |
2007-07-03 |
한국전자통신연구원 |
다중 생체 인식 시스템 및 그 방법
|
|
WO2007036791A1
(en)
*
|
2005-09-28 |
2007-04-05 |
Ranbaxy Laboratories Limited |
Pyrido-pyridimidine derivatives useful as antiinflammatory agents
|
|
CA2624965A1
(en)
*
|
2005-10-07 |
2007-04-19 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of pi3k.alpha.
|
|
KR101538412B1
(ko)
*
|
2005-10-07 |
2015-07-22 |
엑셀리시스, 인코포레이티드 |
ＰＩ３Ｋα의 피리도피리미디논 억제제
|
|
EP2026805A1
(en)
*
|
2006-05-08 |
2009-02-25 |
Astex Therapeutics Limited |
Pharmaceutical combinations of diazole derivatives for cancer treatment
|
|
PL2032134T3
(pl)
|
2006-05-09 |
2015-11-30 |
Genzyme Corp |
Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów
|
|
CA2662768A1
(en)
*
|
2006-09-08 |
2008-03-20 |
Pfizer Products Inc. |
Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
|
|
WO2008032162A1
(en)
|
2006-09-15 |
2008-03-20 |
Pfizer Products Inc. |
Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
|
|
WO2008150260A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Gpc Biotech, Inc. |
8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
|
|
CA2665384A1
(en)
*
|
2006-10-16 |
2008-04-24 |
Gpc Biotech Inc. |
Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
|
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
|
EP2094698A1
(en)
*
|
2006-11-09 |
2009-09-02 |
F. Hoffmann-Roche AG |
Substituted 6-phenyl-pyrido [2,3-d]pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
BRPI0817864A2
(pt)
|
2007-10-05 |
2012-12-25 |
Genzyme Corp |
uso de um composto derivado de ceramida
|
|
JP5537439B2
(ja)
|
2007-12-19 |
2014-07-02 |
アムジエン・インコーポレーテツド |
細胞周期阻害剤としての縮合ピリジン、ピリミジンおよびトリアジン化合物
|
|
MX2010010975A
(es)
|
2008-04-07 |
2010-11-01 |
Amgen Inc |
Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
|
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
|
RS53688B9
(sr)
|
2008-07-08 |
2020-01-31 |
Incyte Holdings Corp |
1,2,5-oksadiazoli kao inhibitori indoleamin 2,3-dioksigenaze
|
|
CA2731685A1
(en)
|
2008-07-28 |
2010-02-04 |
Genzyme Corporation |
Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
|
|
ES2522346T3
(es)
*
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
CN102231984A
(zh)
*
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
|
|
JP2012504645A
(ja)
*
|
2008-10-01 |
2012-02-23 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
|
|
US8309593B2
(en)
*
|
2008-10-03 |
2012-11-13 |
Genzyme Corporation |
2-acylaminopropoanol-type glucosylceramide synthase inhibitors
|
|
PA8852901A1
(es)
*
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
CR20170089A
(es)
|
2009-04-03 |
2017-07-17 |
Plexxikon Inc |
Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas
|
|
EP3718560A3
(en)
|
2009-05-13 |
2020-12-09 |
The University of North Carolina at Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
WO2011025006A1
(ja)
*
|
2009-08-31 |
2011-03-03 |
日本ケミファ株式会社 |
Ｇｐｒ１１９作動薬
|
|
CN102648200A
(zh)
*
|
2009-10-09 |
2012-08-22 |
亚弗克希斯公司 |
用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2，3-d]嘧啶-7(8h)-酮
|
|
JP2013510166A
(ja)
|
2009-11-06 |
2013-03-21 |
プレキシコン インコーポレーテッド |
キナーゼ調節のための化合物、方法およびその適用
|
|
CA2784749C
(en)
*
|
2009-12-18 |
2017-12-12 |
E. Premkumar Reddy |
Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
|
|
AU2010338038B2
(en)
|
2009-12-31 |
2015-07-09 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Tricyclic compounds for use as kinase inhibitors
|
|
RU2589696C2
(ru)
*
|
2010-04-13 |
2016-07-10 |
Новартис Аг |
КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 4 ИЛИ ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 6 (CDK4/6) И ИНГИБИТОР mTOR, ДЛЯ ЛЕЧЕНИЯ РАКА
|
|
TWI510487B
(zh)
|
2010-04-21 |
2015-12-01 |
Plexxikon Inc |
用於激酶調節的化合物和方法及其適應症
|
|
EP2580217A4
(en)
*
|
2010-06-10 |
2014-06-18 |
Afraxis Holdings Inc |
6- (ETHYNYL-) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
|
|
US9376664B2
(en)
|
2010-06-14 |
2016-06-28 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
JP5512894B2
(ja)
|
2010-08-05 |
2014-06-04 |
テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション |
２−置換−８−アルキル−７−オキソ−７，８−ジヒドロピリド［２，３ｄ］ピリミジン−６−カルボニトリル及びその使用
|
|
EP3381920B1
(en)
|
2010-10-25 |
2019-03-27 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
AU2011329763A1
(en)
|
2010-11-17 |
2013-05-09 |
Brigham And Women's Hospital |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
|
US9624213B2
(en)
|
2011-02-07 |
2017-04-18 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
PT2688887E
(pt)
|
2011-03-23 |
2015-07-06 |
Amgen Inc |
Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
|
|
AU2012262489A1
(en)
|
2011-05-27 |
2013-04-04 |
Icahn School Of Medicine At Mount Sinai |
Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof
|
|
JP6431770B2
(ja)
*
|
2012-03-14 |
2018-11-28 |
ルピン・リミテッド |
Ｍｅｋインヒビターとしてのヘテロシクリル化合物
|
|
CA2868966C
(en)
|
2012-03-29 |
2021-01-26 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
CA2878412A1
(en)
|
2012-07-11 |
2014-01-16 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
AU2013296237B2
(en)
|
2012-08-03 |
2019-05-16 |
Foundation Medicine, Inc. |
Human papilloma virus as predictor of cancer prognosis
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
AU2013302519B2
(en)
|
2012-08-17 |
2017-11-02 |
Concert Pharmaceuticals, Inc. |
Deuterated baricitinib
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
HUE040434T2
(hu)
*
|
2013-02-21 |
2019-03-28 |
Pfizer |
Szelektív CDK4/6 inhibitor szilárd alakjai
|
|
SI2968290T1
(sl)
|
2013-03-15 |
2020-02-28 |
G1 Therapeutics, Inc., |
Prehodna zaščita normalnih celic med kemoterapijo
|
|
EP2967050A4
(en)
|
2013-03-15 |
2016-09-28 |
G1 Therapeutics Inc |
HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS
|
|
MX2015012741A
(es)
*
|
2013-03-15 |
2016-02-19 |
Concert Pharmaceuticals Inc |
Palbociclib deuterado.
|
|
AU2014253798C1
(en)
|
2013-04-19 |
2019-02-07 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2014183520A1
(zh)
*
|
2013-05-17 |
2014-11-20 |
上海恒瑞医药有限公司 |
吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
MX2016005297A
(es)
|
2013-10-25 |
2016-08-12 |
Blueprint Medicines Corp |
Inhibidores del receptor del factor de crecimiento de fibroblastos.
|
|
JP6678584B2
(ja)
*
|
2013-12-20 |
2020-04-22 |
バイオメッド バレー ディスカバリーズ，インコーポレイティド |
Ｃｄｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置
|
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
US9796701B2
(en)
|
2013-12-31 |
2017-10-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
US20150297608A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents
|
|
WO2015181737A1
(en)
|
2014-05-28 |
2015-12-03 |
Piramal Enterprises Limited |
Pharmaceutical combination for the treatment of cancer
|
|
CN106687454B8
(zh)
*
|
2014-07-24 |
2019-08-30 |
贝达医药公司 |
作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途
|
|
WO2016015598A1
(en)
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
|
|
EP3174878A4
(en)
*
|
2014-07-31 |
2017-12-27 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of palbociclib
|
|
US20170224819A1
(en)
*
|
2014-08-11 |
2017-08-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
|
|
WO2016024249A1
(en)
*
|
2014-08-14 |
2016-02-18 |
Sun Pharmaceutical Industries Limited |
Crystalline forms of palbociclib
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
CN105111201B
(zh)
*
|
2014-10-16 |
2017-01-11 |
上海页岩科技有限公司 |
5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
WO2016066420A1
(en)
*
|
2014-10-29 |
2016-05-06 |
Sandoz Ag |
Crystalline forms of palbociclib monohydrochloride
|
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
|
CN105616418A
(zh)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂的药物制剂及其制备方法
|
|
US20170306046A1
(en)
|
2014-11-12 |
2017-10-26 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CN104447743B
(zh)
*
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
帕博西尼的制备方法
|
|
CN104496983B
(zh)
*
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
一种帕博西尼的制备方法
|
|
WO2016090257A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Crystal Pharmatech Inc. |
Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
|
|
WO2016092442A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of crystalline forms of palbociclib acetate
|
|
CN105732615B
(zh)
*
|
2014-12-31 |
2018-05-01 |
山东轩竹医药科技有限公司 |
Cdk激酶抑制剂
|
|
EP4205743A1
(en)
|
2014-12-31 |
2023-07-05 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical composition and preparation method therefor
|
|
CN104610254B
(zh)
*
|
2015-01-26 |
2017-02-01 |
新发药业有限公司 |
一种帕博赛布的低成本制备方法
|
|
CZ201589A3
(cs)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Pevné formy soli Palbociclibu
|
|
TWI690533B
(zh)
|
2015-02-12 |
2020-04-11 |
南北兄弟藥業投資有限公司 |
Ｃｄｋ類小分子抑制劑的化合物及其用途
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
ES2751669T3
(es)
|
2015-02-20 |
2020-04-01 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores FGFR
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
|
EP3078663A1
(en)
|
2015-04-09 |
2016-10-12 |
Sandoz Ag |
Modified particles of palbociclib
|
|
WO2016169422A1
(zh)
*
|
2015-04-22 |
2016-10-27 |
江苏恒瑞医药股份有限公司 |
一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
|
|
TWI696617B
(zh)
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
|
TWI714590B
(zh)
*
|
2015-05-29 |
2021-01-01 |
日商帝人製藥股份有限公司 |
吡啶並［３，４－ｄ］嘧啶衍生物及其藥學上可被許可的鹽
|
|
PT3302565T
(pt)
*
|
2015-06-04 |
2020-01-14 |
Pfizer |
Formas de dosagem sólida de palbociclib
|
|
CN104892604B
(zh)
*
|
2015-06-19 |
2016-08-24 |
北京康立生医药技术开发有限公司 |
一种cdk4抑制剂的合成方法
|
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
|
EP3543235A1
(en)
|
2015-08-05 |
2019-09-25 |
ratiopharm GmbH |
Crystalline form and acetic acid adduct of palbociclib
|
|
CN105085517B
(zh)
*
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
一种结晶型帕博西尼游离碱水合物及其制备方法
|
|
CN105130986B
(zh)
*
|
2015-09-30 |
2017-07-18 |
广州科擎新药开发有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其应用
|
|
HU230962B1
(hu)
|
2015-10-28 |
2019-06-28 |
Egis Gyógyszergyár Zrt. |
Palbociclib sók
|
|
CN106632311B
(zh)
*
|
2015-11-02 |
2021-05-18 |
上海科胜药物研发有限公司 |
一种帕博西尼晶型a和晶型b的制备方法
|
|
IL258768B2
(en)
|
2015-11-12 |
2023-11-01 |
Siamab Therapeutics Inc |
Compounds interacting with glycans and methods of use
|
|
CN105418603A
(zh)
*
|
2015-11-17 |
2016-03-23 |
重庆莱美药业股份有限公司 |
一种高纯度帕布昔利布及其反应中间体的制备方法
|
|
CN106810536A
(zh)
*
|
2015-11-30 |
2017-06-09 |
甘李药业股份有限公司 |
一种蛋白激酶抑制剂及其制备方法和医药用途
|
|
WO2017101763A1
(en)
|
2015-12-13 |
2017-06-22 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocycles useful as anti-cancer agents
|
|
CN105418609B
(zh)
*
|
2015-12-31 |
2017-06-23 |
山东大学 |
4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
|
|
US10662186B2
(en)
|
2015-12-31 |
2020-05-26 |
Shanghai Pharmaceuticals Holding Co., Ltd. |
Substituted pyrimidines as cyclin-dependent kinase inhibitors
|
|
CN106967061A
(zh)
*
|
2016-01-13 |
2017-07-21 |
常州方楠医药技术有限公司 |
帕博西林的盐、晶型及其制备方法
|
|
WO2017130219A1
(en)
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
|
WO2017145054A1
(en)
|
2016-02-24 |
2017-08-31 |
Lupin Limited |
Modified particles of crystalline palbociclib free base and process for the preparation thereof
|
|
WO2017161253A1
(en)
|
2016-03-18 |
2017-09-21 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
|
CN107266421B
(zh)
*
|
2016-04-08 |
2020-12-04 |
正大天晴药业集团股份有限公司 |
取代的苯并咪唑类衍生物
|
|
CN107286180B
(zh)
*
|
2016-04-11 |
2019-07-02 |
上海勋和医药科技有限公司 |
杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
|
|
WO2017185031A1
(en)
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
CN106336411B
(zh)
*
|
2016-04-27 |
2018-03-06 |
上海医药集团股份有限公司 |
Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
|
|
CN105949189B
(zh)
*
|
2016-06-05 |
2017-09-22 |
童明琼 |
一种用于治疗乳腺癌的帕博西尼的制备方法
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
|
RU2019102647A
(ru)
|
2016-07-01 |
2020-08-03 |
Г1 Терапьютикс, Инк. |
Антипролиферационные средства на основе пиримидина
|
|
US10807978B2
(en)
|
2016-07-04 |
2020-10-20 |
Dr. Reddy's Laboratories Limited |
Process for preparation of palbociclib
|
|
US10597393B2
(en)
|
2016-07-07 |
2020-03-24 |
Plantex Ltd. |
Solid state forms of Palbociclib dimesylate
|
|
MA45920B1
(fr)
|
2016-08-15 |
2021-08-31 |
Pfizer |
Inhibiteurs de pyridopyrimidinone cdk2/4/6
|
|
IL264950B2
(en)
|
2016-08-23 |
2024-01-01 |
Eisai R&D Man Co Ltd |
Combined treatments for the treatment of malignant liver cell carcinoma
|
|
CN110022900A
(zh)
|
2016-09-08 |
2019-07-16 |
蓝图药品公司 |
成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
|
|
WO2018065999A1
(en)
|
2016-10-07 |
2018-04-12 |
Mylan Laboratories Limited |
Novel polymorph of an intermediate for palbociclib synthesis
|
|
WO2018073574A1
(en)
|
2016-10-20 |
2018-04-26 |
Cipla Limited |
Polymorphic forms of palbociclib
|
|
RU2019111887A
(ru)
|
2016-10-20 |
2020-11-20 |
Пфайзер Инк. |
Антипролиферативные средства для лечения лаг
|
|
CN106565707B
(zh)
*
|
2016-11-03 |
2019-01-04 |
杭州科巢生物科技有限公司 |
帕博西尼新合成方法
|
|
US11865176B2
(en)
|
2016-11-08 |
2024-01-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
|
WO2018091999A1
(en)
|
2016-11-16 |
2018-05-24 |
Pfizer Inc. |
Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
AU2017364805B2
(en)
|
2016-11-28 |
2021-12-16 |
Teijin Pharma Limited |
Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
|
|
US11084814B2
(en)
|
2016-11-28 |
2021-08-10 |
Teijin Pharma Limited |
Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
|
|
MX2019006843A
(es)
|
2016-12-16 |
2019-11-11 |
Cstone Pharmaceuticals |
Inhibidor de cdk4/6.
|
|
BR112019013814A2
(pt)
|
2017-01-06 |
2020-01-21 |
G1 Therapeutics Inc |
método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
|
|
CN108191857B
(zh)
*
|
2017-01-24 |
2020-10-23 |
晟科药业（江苏）有限公司 |
6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
|
|
US10729692B2
(en)
*
|
2017-02-26 |
2020-08-04 |
Institute For Cancer Research |
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
|
|
US11253609B2
(en)
|
2017-03-03 |
2022-02-22 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
WO2018160076A1
(en)
*
|
2017-03-03 |
2018-09-07 |
Auckland Uniservices Limited |
Fgfr kinase inhibitors and pharmaceutical uses
|
|
US11083722B2
(en)
|
2017-03-16 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of breast cancer
|
|
CN108658855A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种含氮双环化合物及其制备方法和用途
|
|
CN108658854A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种生物碱化合物及其制备方法和作为海洋防污剂的应用
|
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EA201992744A1
(ru)
|
2017-06-16 |
2020-05-27 |
Бета Фарма, Инк. |
Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей
|
|
WO2019006393A1
(en)
|
2017-06-29 |
2019-01-03 |
G1 Therapeutics, Inc. |
MORPHIC FORMS OF GIT38 AND METHODS OF MAKING SAME
|
|
EA036060B1
(ru)
*
|
2017-07-17 |
2020-09-21 |
Пфайзер Инк. |
Пиридопиримидиноновые ингибиторы cdk2/4/6
|
|
EP3658119A1
(en)
|
2017-07-28 |
2020-06-03 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
CN109384767B
(zh)
*
|
2017-08-08 |
2020-05-05 |
江苏恒瑞医药股份有限公司 |
一种吡啶并嘧啶类衍生物的制备方法及其中间体
|
|
US20230160016A1
(en)
|
2017-08-31 |
2023-05-25 |
Novartis Ag |
Methods of selecting a treatment for cancer patients
|
|
CN107488175A
(zh)
*
|
2017-09-04 |
2017-12-19 |
上海微巨实业有限公司 |
一种帕博西林关键中间体的制备方法
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
BR112020012635A2
(pt)
|
2017-12-22 |
2020-12-01 |
Ravenna Pharmaceuticals, Inc. |
derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase
|
|
CN108586452A
(zh)
*
|
2018-01-12 |
2018-09-28 |
重庆市碚圣医药科技股份有限公司 |
一种帕博西尼中间体的合成方法
|
|
KR20200115583A
(ko)
|
2018-01-29 |
2020-10-07 |
베타 파마, 인크. |
Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도
|
|
CN108218861B
(zh)
*
|
2018-02-05 |
2019-07-23 |
黑龙江中医药大学 |
一种预防和治疗糖尿病的药物及其制备方法
|
|
CN112041307B
(zh)
|
2018-02-06 |
2024-02-09 |
伊利诺伊大学评议会 |
作为选择性雌激素受体降解剂的取代的苯并噻吩类似物
|
|
JP2021514975A
(ja)
|
2018-02-27 |
2021-06-17 |
ファイザー・インク |
サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
|
|
KR20200139153A
(ko)
|
2018-02-27 |
2020-12-11 |
인사이트 코포레이션 |
A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
|
|
EP3788047B1
(en)
|
2018-05-04 |
2024-09-04 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
|
BR112020022373A2
(pt)
|
2018-05-04 |
2021-02-02 |
Incyte Corporation |
sais de um inibidor de fgfr
|
|
AU2019269159A1
(en)
|
2018-05-14 |
2020-11-19 |
Pfizer Inc. |
Oral solution formulation
|
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
|
SI3802529T1
(sl)
|
2018-05-24 |
2024-03-29 |
Synthon B.V. |
Postopek za izdelavo palbocikliba
|
|
IL300821A
(en)
|
2018-07-05 |
2023-04-01 |
Incyte Corp |
Fused pyrazine derivatives as A2A/A2B inhibitors
|
|
BR112021001233A2
(pt)
|
2018-07-23 |
2021-04-20 |
F. Hoffmann-La Roche Ag |
método para tratar câncer em um paciente, uso de uma quantidade terapeuticamente eficaz de gdc-0077 e quantidade terapeuticamente eficaz de gdc-0077
|
|
SG11202101807SA
(en)
|
2018-08-24 |
2021-03-30 |
G1 Therapeutics Inc |
Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
|
|
JP6952747B2
(ja)
|
2018-09-18 |
2021-10-20 |
ファイザー・インク |
がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
|
|
WO2020076432A1
(en)
|
2018-10-08 |
2020-04-16 |
Genentech, Inc. |
Methods of treating cancer with pi3k alpha inhibitors and metformin
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
WO2020114519A1
(zh)
*
|
2018-12-07 |
2020-06-11 |
杭州英创医药科技有限公司 |
作为cdk-hdac双通路抑制剂的杂环化合物
|
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
AU2019413683A1
(en)
*
|
2018-12-28 |
2021-08-12 |
Spv Therapeutics Inc |
Cyclin-dependent kinase inhibitors
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
WO2020157709A1
(en)
|
2019-02-01 |
2020-08-06 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
MX2021009682A
(es)
|
2019-02-15 |
2021-11-12 |
Incyte Corp |
Biomarcadores de cinasa 2 dependientes de ciclinas y sus usos.
|
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
US20220241412A1
(en)
|
2019-05-24 |
2022-08-04 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
US20230053328A9
(en)
|
2019-05-24 |
2023-02-16 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
CN112010844B
(zh)
*
|
2019-05-31 |
2023-07-25 |
中国药科大学 |
N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
|
TW202114685A
(zh)
*
|
2019-06-20 |
2021-04-16 |
大陸商江蘇恒瑞醫藥股份有限公司 |
藥物組合物以及其製備方法
|
|
CN110143948B
(zh)
*
|
2019-06-21 |
2021-05-14 |
上海博悦生物科技有限公司 |
Cdk4/6抑制剂、其药物组合物、制备方法及应用
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
KR20220044527A
(ko)
|
2019-08-01 |
2022-04-08 |
인사이트 코포레이션 |
Ido 억제제의 투여 요법
|
|
KR20220064369A
(ko)
|
2019-08-14 |
2022-05-18 |
인사이트 코포레이션 |
Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
|
|
CN115298177A
(zh)
|
2019-10-11 |
2022-11-04 |
因赛特公司 |
作为cdk2抑制剂的双环胺
|
|
WO2021076602A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN112759589B
(zh)
*
|
2019-11-01 |
2022-04-08 |
暨南大学 |
嘧啶并吡啶酮类化合物及其应用
|
|
EP4065578A1
(en)
|
2019-11-26 |
2022-10-05 |
Theravance Biopharma R&D IP, LLC |
Fused pyrimidine pyridinone compounds as jak inhibitors
|
|
JP2023504436A
(ja)
|
2019-12-03 |
2023-02-03 |
ジェネンテック， インコーポレイテッド |
乳がんの治療のための併用療法
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
CN115023424B
(zh)
*
|
2019-12-16 |
2024-07-02 |
卢内拉生物技术有限公司 |
选择性cdk4/6抑制剂型癌症治疗药物
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US20230117684A1
(en)
|
2020-03-05 |
2023-04-20 |
Pfizer Inc. |
Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
|
|
KR20230017165A
(ko)
|
2020-03-06 |
2023-02-03 |
인사이트 코포레이션 |
Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법
|
|
WO2021183994A1
(en)
*
|
2020-03-13 |
2021-09-16 |
Prosenestar Llc |
Pyrido[2,3-d]pyrimidin-7(8h)-ones as cdk inhibitors
|
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
|
|
EP4135844A1
(en)
|
2020-04-16 |
2023-02-22 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
CA3173678A1
(en)
|
2020-05-19 |
2021-11-25 |
Jay Copeland Strum |
Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
|
|
US20230132667A1
(en)
*
|
2020-05-28 |
2023-05-04 |
University Of Washington |
Drug-like molecules and methods for the therapeutic targeting of viral rna structures
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
CN113880809B
(zh)
|
2020-07-03 |
2022-10-18 |
盛世泰科生物医药技术(苏州)有限公司 |
一种嘧啶类衍生物及其制备方法和应用
|
|
IL299871A
(en)
|
2020-07-15 |
2023-03-01 |
Pfizer |
Methods and combinations of KAT6 inhibitors for the treatment of cancer
|
|
CA3189632A1
(en)
|
2020-07-20 |
2022-01-27 |
Pfizer Inc. |
Combination therapy
|
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
|
WO2022063119A1
(zh)
*
|
2020-09-24 |
2022-03-31 |
南京济群医药科技股份有限公司 |
一种羟乙磺酸哌柏西利的组合物及药物
|
|
CN114306245A
(zh)
|
2020-09-29 |
2022-04-12 |
深圳市药欣生物科技有限公司 |
无定形固体分散体的药物组合物及其制备方法
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
|
WO2022091001A1
(en)
|
2020-10-29 |
2022-05-05 |
Pfizer Ireland Pharmaceuticals |
Process for preparation of palbociclib
|
|
WO2022123419A1
(en)
|
2020-12-08 |
2022-06-16 |
Pfizer Inc. |
Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
|
|
CN112569361B
(zh)
*
|
2020-12-30 |
2023-01-10 |
扬子江药业集团上海海尼药业有限公司 |
一种哌柏西利干混悬组合物及其制备方法
|
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式ヘテロ環
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
CA3224674A1
(en)
|
2021-07-07 |
2023-01-12 |
Pei Gan |
Tricyclic compounds as inhibitors of kras
|
|
JP2024529347A
(ja)
|
2021-07-14 |
2024-08-06 |
インサイト・コーポレイション |
Ｋｒａｓの阻害剤としての三環式化合物
|
|
WO2023009438A1
(en)
|
2021-07-26 |
2023-02-02 |
Celcuity Inc. |
1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
|
|
CA3229855A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
|
CN113683612B
(zh)
*
|
2021-09-07 |
2022-06-17 |
山东铂源药业股份有限公司 |
一种帕布昔利布的制备方法
|
|
WO2023040914A1
(zh)
*
|
2021-09-14 |
2023-03-23 |
甘李药业股份有限公司 |
一种cdk4/6抑制剂的医药用途
|
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
|
WO2023056421A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
WO2023064857A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
|
IL312886A
(en)
|
2021-11-22 |
2024-07-01 |
Incyte Corp |
Combined treatment that includes a Pegfer inhibitor and a Kras inhibitor
|
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
|
CA3240454A1
(en)
|
2021-12-10 |
2023-06-15 |
Lacey Morgan LITCHFIELD |
Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibito
|
|
WO2023111810A1
(en)
|
2021-12-14 |
2023-06-22 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
|
WO2023114264A1
(en)
|
2021-12-15 |
2023-06-22 |
Eli Lilly And Company |
Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
|
|
AU2022418585A1
(en)
|
2021-12-22 |
2024-07-11 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
|
TW202341982A
(zh)
|
2021-12-24 |
2023-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Ｃｄｋ２抑制劑及其用途
|
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
|
AR128717A1
(es)
|
2022-03-07 |
2024-06-05 |
Incyte Corp |
Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
|
|
HUP2200147A1
(hu)
*
|
2022-05-10 |
2023-11-28 |
Egyt Gyogyszervegyeszeti Gyar |
Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény
|
|
TW202413359A
(zh)
|
2022-06-22 |
2024-04-01 |
美商英塞特公司 |
雙環胺ｃｄｋ１２抑制劑
|
|
EP4302832A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing glucono delta lactone
|
|
EP4302755A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing an amino acid
|
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
CN117430597A
(zh)
*
|
2022-07-14 |
2024-01-23 |
浙江同源康医药股份有限公司 |
用作cdk4激酶抑制剂的化合物及其应用
|
|
WO2024023703A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
|
|
WO2024049926A1
(en)
|
2022-08-31 |
2024-03-07 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders
|
|
WO2024097206A1
(en)
|
2022-11-02 |
2024-05-10 |
Petra Pharma Corporation |
Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
|
|
WO2024100236A1
(en)
|
2022-11-11 |
2024-05-16 |
Astrazeneca Ab |
Combination therapies for the treatment of cancer
|
|
WO2024125581A2
(zh)
*
|
2022-12-16 |
2024-06-20 |
上海岸阔医药科技有限公司 |
化合物及其用途
|
|
WO2024132652A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024133726A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|